Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) ; volume:10 ; number:1 ; day:26 ; month:6 ; year:2017 ; pages:1-8 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (26.6.2017), 1-8, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
- Beteiligte Personen und Organisationen
-
Giagounidis, Aristoteles
Selleslag, Dominik
Beyne-Rauzy, Odile
Mittelman, Moshe
Muus, Petra
Nimer, Stephen D.
Hellström-Lindberg, Eva
Powell, Bayard L.
Guerci-Bresler, Agnes
Sekeres, Mikkael A.
Deeg, H. Joachim
Del Cañizo, Consuelo
Greenberg, Peter L.
Shammo, Jamile M.
Skikne, Barry
Yu, Xujie
List, Alan F.
SpringerLink (Online service)
- DOI
-
10.1186/s13045-017-0491-2
- URN
-
urn:nbn:de:1111-201709212877
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fenaux, Pierre
- Giagounidis, Aristoteles
- Selleslag, Dominik
- Beyne-Rauzy, Odile
- Mittelman, Moshe
- Muus, Petra
- Nimer, Stephen D.
- Hellström-Lindberg, Eva
- Powell, Bayard L.
- Guerci-Bresler, Agnes
- Sekeres, Mikkael A.
- Deeg, H. Joachim
- Del Cañizo, Consuelo
- Greenberg, Peter L.
- Shammo, Jamile M.
- Skikne, Barry
- Yu, Xujie
- List, Alan F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Association between RBC transfusion and 1-year mortality in ICU survivors
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
RBC transfusion and necrotizing enterocolitis in very preterm infants: a multicenter observational study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Association between RBC transfusion and 1-year mortality in ICU survivors
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
RBC transfusion and necrotizing enterocolitis in very preterm infants: a multicenter observational study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Association between RBC transfusion and 1-year mortality in ICU survivors
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
RBC transfusion and necrotizing enterocolitis in very preterm infants: a multicenter observational study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q